Cingulate Therapeutics: BDD Pharma and Cingulate Therapeutics Announce License Agreement With OralogiK Enabled Triple Pulse Products
BDD Pharma, a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations, and Cingulate Therapeutics, a clinical stage biopharmaceutical company, today announced that the companies have completed a license agreement for BDD's OralogiK™ timed drug delivery technology
Read full article »
Cingulate Therapeutics focuses on the development of therapies for the treatment of central nervous system and neurobiological disorders.
Read more